Given that EGFR and PI3K/AKT pathways remain actionable in HNSCC, these findings support the use of BET inhibitors in combination with anti-EGFR therapies or PI3K/AKT inhibitors, strategies that have shown preclinical synergy in HNSCC models.95 The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.